Skip to main content Skip to main navigation menu Skip to site footer

Differences in AGEs-N-Carboxymethyllysine and Kidney Injury Molecule-1 in non-diabetic subjects, diabetic with and without diabetic nephropathy

  • Dwi Fajaryani ,
  • Muji Rahayu ,
  • Banundari Rachmawati ,


Abstract

Background: Diabetic nephropathy (ND) is a complication of diabetes mellitus (DM), characterized by persistent albuminuria. N-carboxymethyl lysine (CML) is the most extensive advanced glycation end products (AGEs), formed from the fructoselysine amadori. Kidney Injury Molecule 1 (KIM-1) is a type 1 transmembrane glycoprotein. The aim of the study is to analyze the differences in AGEs-CML and KIM-1 levels in the non-DM subject, DM without and with DN.

Methods: A cross-sectional analytic observational study was conducted on 25 non-DM subjects (K1), 25 DM without DN (K2), and 25 DM with  DN (K3) in PROLANIS Semarang. AGEs-CML and KIM-1 levels were measured using the ELISA method. Inter-group AGEs-CML levels were analyzed using the One way ANOVA test, followed by post hoc Games-Howell. The levels KIM-1 between groups were analyzed using the Kruskal-Wallis test levels, followed by Mann Whitney post hoc test and p<0.05, were considered significant.

Results: There were differences in AGEs-CML levels between K1 (739.89±227.37 ng/ml) and K3 (911.79±107.44) (p = 0.005), between K2 (798.82±153.03) and K3 (911.79 ± 107.44) (p = 0.012) and there was no difference in K1 and K2 (p =0.535). There were differences in KIM-1 level between K1 [9.82 (5.99 – 14.83) pg/ml] and K2 [15.31 (10.12 – 30.21) (p <0.001)], between K1 [9.82 (5.99 – 14.83)] and K3 [15.11 (8.27 – 25.63) (p <0.001)] and there was no difference between K2 and K3 (p=0.720)

Conclusion: The highest AGEs-CML levels were significantly found in the K3 group, followed by K2 and the lowest in K3. KIM-1 levels were significantly found in the K2 group, followed by K3 and the lowest in K1.

Keywords: diabetes urine nephropathy product.

References

  1. Soelistijo SA, Novida H, Rudijanto A, Pradana S, Suastika K, Manaf A. Consensus on the Management and Prevention of Type 2 Diabetes Mellitus in Indonesia 2015. Indonesian Diabetic Association. 2015.
  2. Riddle MC. The Journal of clinical and applied research and Education Diabetes Care. Am Diabetes Assoc. 2019;42:204.
  3. International Diabetes Federations response to the 3rd UN HLM on NCDs political declaration. IDF. 2018;1–10.
  4. Mihardja L, Delima D, Massie RGA, Karyana M, Nugroho P, Yunir E. Prevalence of kidney dysfunction in diabetes mellitus and associated risk factors among productive age Indonesian. J Diabetes Metab Disord. 2018;17(29):53–61.
  5. Gheith O, Farouk N, Nampoory N, Halim MA, Al-otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factor. J Nephropharmacol. 2016;5(1):49–56.
  6. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012;27(4):269-73. doi: 10.5001/omj.2012.68
  7. Lim AKh. Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361-81. doi: 10.2147/IJNRD.S40172.
  8. Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl. 2018;8(1):2–7.
  9. Lee SY, Chol ME. Albuminuria, Urinary biomarkers for early diabetic nephropathy: Beyond. HHS Public Access. 2016;30(7):1063–75.
  10. Robles NR, Villa J, Gallego RH. Non-Proteinuric Diabetic Nephropathy. J Clin Med. 2015;4:1761–73.
  11. Gluhovschi C, Gluhovschi G, Petrica L, Timar R, Velciov S, Ionita I, Kaycsa A, Timar B. Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy. J Diabetes Res. 2016;2016:4626125. doi: 10.1155/2016/4626125.
  12. Uwaezuoke SN. The role of novel biomarkers in predicting diabetic nephropathy : a review. Int J Nephrol Renovasc Dis. 2017;10:221–31.
  13. Rabbani N, Thornalley PJ. Advanced glycation end products in the pathogenesis of chronic kidney disease. Kidney Int. 2018;93(4):803–13.
  14. Brings S, Fleming T, Freichel M, Muckenthaler MU, Herzig S, Nawroth PP. Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention. Int J Mol Sci. 2017;18(5):984. doi: 10.3390/ijms18050984.
  15. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci. 2013;152:139–52.
  16. Tang SCW, Leung CK, Neng K. Diabetic Tubulopathy: An Emerging Entity. Diabetes and the kidney. 2011;170:124–34.
  17. Petrica L, Vlad A, Gluhovschi G, Zamfir A, Popescu C, Gadalean F, et al. Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus. Int J Clin. 2015;8(2):2516–25.
  18. Moresco RN, Bochi G V, Stein CS, Carvalho JAM De, Cembranel BM, Bollick YS. Clinica Chimica Acta Urinary kidney injury molecule-1 in renal disease. Clin Chim Acta. 2018;487:15–21.
  19. Gale EAM, Gillespie KM. Diabetes and gender. Diabetologia. 2001;44:3–15.
  20. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk Factors for Renal Dysfunction in Type 2 Diabetes. Diabetes. 2006;55:1832–9.
  21. Gitanjali G, Goyal S, Panag K. Role of Urinary Albumin To Creatinine Ratio and Spot Albuminuria in Predicting Significant Albuminuria in Patients of Diabetic Nephropathy. J Evol Med Dent Sci. 2014;3(01):38–45.
  22. Lim A. Diabetic nephropathy – complications and treatment. Int J Nephrol Renovasc Dis. 2014;47:361–81.
  23. Meigs J, D’Agostino R, Nathan D, Rifai N, Wilson P. Longitudinal Association of Glycemia and Microalbuminuria The Framingham Offspring Study. Epidemiol Heal Serv Psychosoc Res. 2002;25(6):977–83.
  24. Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, et al. Pathologic Classification of Diabetic Nephropathy. J Am Soc Nephrol. 2010;21:556–63.
  25. Coughlan MT, Patel K, Jerums G, Penfold A, Macisaac RJ, Forbes M. Advanced Glycation Urinary Protein-Bound Biomarkers and Severity of Diabetic Nephropathy in Man. Am J Nephrol. 2011;34:347–55.
  26. Friess U, Waldner M, Wahl HG, Lehmann R, Haring HU, Voelter W, et al. Liquid chromatography-based determination of urinary free and total N(epsilon)-(carboxymethyl)lysine excretion in normal and diabetic subjects. J Chromatogr B Anal Technol Biomed Life Sci. 2003;794(2):273–80.
  27. Wagner Z, Wittmann I, Mazak I, Schinzel R, Heidland A, Kientsch-Engel R. N-Carboxymethyllysine Levels in Patients With Type 2 Diabetes: Role of Renal Function. Am J kidney Dis. 2001;38(4):785–91.
  28. Morcos M, Sayed AAR, Bierhaus A, Yard B, Merz W, Kloeting I, et al. Activation of Tubular Epithelial Cells in Diabetic. Diabetes. 2002;51:21–4.
  29. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237-44. doi: 10.1046/j.1523-1755.2002.00433.x.
  30. Aslan O, Demir M, Koseoglu M. Kidney Injury Molecule Levels in Type 2 Diabetes Mellitus. J Clin Lab Anal. 2016;1036:1031–6.
  31. Ahmed SA, Hamed MA. Kidney injury molecule-1 as a predicting factor for inflamed kidney , diabetic and diabetic nephropathy Egyptian patients. Journal diabetes Metab Disord. 2015;14(6):1–6.
  32. Zylka A, Paulina D, Beata C, Anieszka B, Piotr C. Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients. Mediators of Inflammation. 2018;1–12.
  33. Tekce BK. Evaluation of the Urinary Kidney Injury Molecule-1 Levels in Patients With Diabetic Nephropathy. 2014;37(6):377–83.

How to Cite

Fajaryani, D., Rahayu, M., & Rachmawati, B. (2021). Differences in AGEs-N-Carboxymethyllysine and Kidney Injury Molecule-1 in non-diabetic subjects, diabetic with and without diabetic nephropathy. Bali Medical Journal, 10(1), 325–330. https://doi.org/10.15562/bmj.v10i1.2175
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
13

Share

Search Panel

Dwi Fajaryani
Google Scholar
Pubmed
BMJ Journal

Muji Rahayu
Google Scholar
Pubmed
BMJ Journal

Banundari Rachmawati
Google Scholar
Pubmed
BMJ Journal